Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
Type
Public
HQ
Newton, US
Founded
2001
Employees
41 (est)+71%
Chiasma was founded in 2001 and is headquartered in Newton, US

Key People at Chiasma

Chaime Orlev

Chaime Orlev

VP of Finance and Administration
Roni Mamluk

Roni Mamluk

CEO
Dana Gelbaum

Dana Gelbaum

VP of BD and Supply Chain
David Caron

David Caron

VP CMC and Pharmaceutical Development
Shoshie Katz

Shoshie Katz

VP of Quality Assurance & Regulatory Affairs
Asi Haviv

Asi Haviv

VP of Clinical Development
Lillian Kuan

Lillian Kuan

Alumni Advisory Committee Board Member

Chiasma Locations

Newton, US
Jerusalem, IL

Chiasma Metrics

Chiasma Summary

Market capitalization

$46.3 M

Closing share price

$1.9
Chiasma's latest market capitalization is $46.3 M.

Chiasma Market Value History

Chiasma Company Life

You may also be interested in